Concepts (61)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Viral Vaccines | 1 | 2022 | 24 | 0.780 |
Why?
|
| Antibodies, Neutralizing | 5 | 2024 | 303 | 0.630 |
Why?
|
| Moths | 1 | 2017 | 1 | 0.590 |
Why?
|
| DNA-Directed DNA Polymerase | 1 | 2017 | 8 | 0.590 |
Why?
|
| Viral Proteins | 1 | 2017 | 30 | 0.590 |
Why?
|
| DNA, Viral | 1 | 2017 | 165 | 0.550 |
Why?
|
| AIDS Vaccines | 4 | 2024 | 152 | 0.520 |
Why?
|
| HIV Antibodies | 4 | 2024 | 247 | 0.480 |
Why?
|
| HIV-1 | 6 | 2024 | 1260 | 0.410 |
Why?
|
| Immunoglobulin Heavy Chains | 1 | 2024 | 8 | 0.240 |
Why?
|
| DNA Copy Number Variations | 1 | 2024 | 22 | 0.240 |
Why?
|
| Polymorphism, Genetic | 1 | 2024 | 99 | 0.230 |
Why?
|
| Neutralization Tests | 2 | 2020 | 108 | 0.210 |
Why?
|
| HIV Envelope Protein gp120 | 3 | 2020 | 104 | 0.200 |
Why?
|
| Animals | 3 | 2024 | 1081 | 0.200 |
Why?
|
| Immunoglobulin Class Switching | 1 | 2020 | 6 | 0.180 |
Why?
|
| Phylogeny | 2 | 2019 | 231 | 0.180 |
Why?
|
| Antibodies, Viral | 1 | 2022 | 284 | 0.170 |
Why?
|
| Epitopes | 2 | 2020 | 97 | 0.160 |
Why?
|
| Genetic Variation | 2 | 2017 | 175 | 0.160 |
Why?
|
| Genitalia, Female | 1 | 2019 | 17 | 0.160 |
Why?
|
| HIV Envelope Protein gp160 | 1 | 2019 | 22 | 0.160 |
Why?
|
| Vagina | 1 | 2019 | 91 | 0.160 |
Why?
|
| HIV Infections | 5 | 2024 | 5097 | 0.160 |
Why?
|
| RNA, Viral | 2 | 2019 | 303 | 0.150 |
Why?
|
| Antibodies, Monoclonal | 1 | 2019 | 142 | 0.150 |
Why?
|
| Denaturing Gradient Gel Electrophoresis | 1 | 2017 | 1 | 0.150 |
Why?
|
| Serial Passage | 1 | 2017 | 5 | 0.150 |
Why?
|
| Larva | 1 | 2017 | 42 | 0.150 |
Why?
|
| Humans | 7 | 2024 | 14537 | 0.140 |
Why?
|
| Superinfection | 1 | 2015 | 8 | 0.130 |
Why?
|
| Peptide Fragments | 1 | 2015 | 37 | 0.130 |
Why?
|
| env Gene Products, Human Immunodeficiency Virus | 2 | 2024 | 52 | 0.100 |
Why?
|
| Immunoglobulin Variable Region | 1 | 2024 | 9 | 0.060 |
Why?
|
| Transcriptome | 1 | 2024 | 14 | 0.060 |
Why?
|
| Disease Models, Animal | 1 | 2024 | 45 | 0.060 |
Why?
|
| Alleles | 1 | 2024 | 143 | 0.060 |
Why?
|
| Antibody Formation | 1 | 2024 | 61 | 0.060 |
Why?
|
| Immunization | 1 | 2024 | 63 | 0.060 |
Why?
|
| Female | 3 | 2024 | 9103 | 0.050 |
Why?
|
| Antibody Affinity | 1 | 2019 | 11 | 0.040 |
Why?
|
| Complementarity Determining Regions | 1 | 2019 | 11 | 0.040 |
Why?
|
| B-Lymphocytes | 1 | 2019 | 34 | 0.040 |
Why?
|
| Protein Binding | 1 | 2019 | 62 | 0.040 |
Why?
|
| Organ Specificity | 1 | 2019 | 10 | 0.040 |
Why?
|
| Reproductive Tract Infections | 1 | 2019 | 8 | 0.040 |
Why?
|
| CD4 Antigens | 1 | 2019 | 49 | 0.040 |
Why?
|
| Amino Acid Sequence | 1 | 2019 | 139 | 0.040 |
Why?
|
| Polysaccharides | 1 | 2019 | 45 | 0.040 |
Why?
|
| South Africa | 2 | 2024 | 7596 | 0.040 |
Why?
|
| Viremia | 1 | 2019 | 66 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2019 | 435 | 0.040 |
Why?
|
| HIV Seropositivity | 1 | 2019 | 265 | 0.030 |
Why?
|
| Antigenic Variation | 1 | 2015 | 7 | 0.030 |
Why?
|
| Sequence Analysis, RNA | 1 | 2015 | 17 | 0.030 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2015 | 48 | 0.030 |
Why?
|
| Viral Load | 1 | 2019 | 819 | 0.030 |
Why?
|
| Male | 1 | 2024 | 6754 | 0.030 |
Why?
|
| Adolescent | 1 | 2019 | 2985 | 0.020 |
Why?
|
| Middle Aged | 1 | 2019 | 3601 | 0.020 |
Why?
|
| Adult | 1 | 2019 | 5913 | 0.020 |
Why?
|